Author Claim Review

 Quick Explanation Copied

 Long Explanation

Scientific Strength of Michael J. Moore

Based on 17 publications indexed in the BGPT evidence layer, Moore's work spans molecular genetics, vector biology, public health epidemiology, neuroscience, and biomedical engineering. The scientific output is characterized by methodological diversity and consistently strong mechanistic reasoning.

Key Strengths

Mechanistic depth: The 2013 PQBP1 study in Genes & Development systematically connects alternative splicing (SF3B1-mediated), neuronal morphology, and intellectual disability through multi-layered evidence including CLIP, RNA-seq, shRNA rescue, and Sholl analysis across independent experiments [GSE44402 data deposited].

Large-scale rigor: The 2026 RBC proteome atlas (n=13,091) and 2026 cortical morphometry mega-analysis (n=9,647) demonstrate capacity for population-scale multi-omics and harmonized cross-dataset analyses with rigorous corrections and QC.

Translation: The 2024 Cambodia malaria vector-control field trial achieves 94–95% protective efficacy with carefully designed Latin-square sampling and robust negative-binomial modeling.

Limitations and Blindspots

Several works rely on overexpression systems (p63 isoform study, TDP-43 study) or murine models (BK-TriGs hemostatic microgels, IFN-γ K. pneumoniae) that lack direct human in vivo validation. Some studies report incomplete data availability statements (p63 isoform paper) or limited sample sizes (IBS hypnotherapy RCT n=51; THR AE cohort n=417). Cross-species generalization is a recurring issue noted by Moore himself in the miR-33 and PQBP1 papers.

Publication Track Record

Moore publishes in high-impact venues (Science, Cell, Science Advances, Genes & Development, Scientific Reports, American Journal of Public Health, Journal of Trauma and Acute Care Surgery). The RBC proteome atlas alone is linked to provisional patent applications, suggesting translational ambition. The preponderance of work is co-authored with established institutional groups (Washington University, Rockefeller, Notre Dame, NIH-funded centers).

 BGPT Author Review

Scientific Quality

Moore demonstrates strong scientific acumen across a wide range of disciplines. His most impactful works (miR-33, RBC atlas, PQBP1) combine rigorous multi-omics with mechanistic validation. Weaknesses include reliance on overexpression systems, limited in vivo human validation for several key findings, and some data-deposition gaps.

Communication Quality

Papers generally well-structured with clear mechanistic logic and explicit limitation reporting. Some works lack clear data-availability statements or have incomplete supplementary documentation. The 2026 somatic mutation atlas and p63 study demonstrate strong scientific writing.

Author Novelty

Moore consistently produces novel findings: germline-targeting HIV immunogens (Cell 2015), miR-33 cholesterol regulation (Science 2010), population-scale RBC aging clocks (2026), and orthogonally targeted radiosensitization (2026). Few purely derivative works among indexed papers.

Scientific Rigor

Strong methodological rigor in high-profile works (RE-NanoSeq, DIA-PASEF, Latin-square field trials, mega-analysis harmonization). However, several studies show incomplete sample-size reporting, reliance on single-cell lines, missing controls (e.g., lack of CD4/NK quantification in some arms), and limited power in some RCTs.